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Abstract
Purpose To assess the sustained and acute effects, as well as the influence of sustained consumption on the acute effects, of 
orange juice (OJ) with a natural hesperidin content and hesperidin-enriched OJ (EOJ) on blood (BP) and pulse (PP) pressures 
in pre- and stage-1 hypertensive individuals.
Methods In a randomized, parallel, double-blind, placebo-controlled trial, participants (n = 159) received 500 mL/day of 
control drink, OJ, or EOJ for 12 weeks. Two dose–response studies were performed at baseline and after 12 weeks.
Results A single EOJ dose (500 mL) reduced systolic BP (SBP) and PP, with greater changes after sustained treatment where 
a decrease in diastolic BP (DBP) also occurred (P < 0.05). SBP and PP decreased in a dose-dependent manner relative to 
the hesperidin content of the beverages throughout the 12 weeks (P < 0.05). OJ and EOJ decreased homocysteine levels at 
12 weeks versus the control drink (P < 0.05). After 12 weeks of EOJ consumption, four genes related to hypertension (PTX3, 
NLRP3, NPSR1 and NAMPT) were differentially expressed in peripheral blood mononuclear cells (P < 0.05).
Conclusion Hesperidin in OJ reduces SBP and PP after sustained consumption, and after a single dose, the chronic consump-
tion of EOJ enhances its postprandial effect. Decreases in systemic and transcriptomic biomarkers were concomitant with 
BP and PP changes. EOJ could be a useful co-adjuvant tool for BP and PP management in pre- and stage-1 hypertensive 
individuals.
Keywords Orange juice · Hesperidin · Blood pressure · Pulse pressure · Pre-hypertension
Introduction
Flavonoid compounds are the most abundant phenolic 
compounds in plants, and citrus flavonoids, particularly 
present in orange juice (OJ), are attracting attention due to 
their beneficial effects on cardiovascular risk factors [1].
OJ is a main dietary source of flavanones, a subclass of 
flavonoids, and hesperetin-7-O-rutinoside (hesperidin) and 
naringenin-7-O-rutinoside (narirutin) are the main citrus 
flavanone components [2].
Data from cohort studies reported an inverse associa-
tion between citrus fruit/flavanone consumption and cer-
ebrovascular disease [3–5] and cardiovascular mortality 
[6–8]. Antihypertensive, antithrombotic, anti-inflamma-
tory, antilipemic, vasodilator, and antioxidant effects of 
hesperidin have been reported in animal models [9–11]. 
Similar outcomes have been observed for narirutin [12].
Recently, hesperidin has been shown to reduce the ath-
erosclerotic plaque area and macrophage foam cell forma-
tion in low density lipoprotein (LDL) receptor-deficient 
mice [11]. The aforementioned properties of hesperidin 
have been considered to be the mechanisms responsible 
for the beneficial effects of citrus flavanone consumption 
on cardiovascular disease in humans [13].
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Concerning the antihypertensive effects of citrus fla-
vanones, data from animal studies showed that hespere-
tin, a biological metabolite of hesperidin [10], exerts an 
antihypertensive effect in hypertensive rats but not in 
normotensive rats [9, 14]. The antihypertensive effect, 
as well as vasodilatory and anti-inflammatory activities, 
has been reported to be mediated by the hesperetin-7-O-
β-d-glucuronide conjugate [10]. In humans, a natural OJ, 
but not a hesperidin-enriched beverage, decreased blood 
pressure (BP) in overweight and obese individuals [15]. 
Similarly, chronic consumption of hesperidin reduced BP 
in type 2 diabetes patients [16], although no hypotensive 
effect was observed in healthy or overweight individuals 
[17, 18]. In individuals at moderate risk of cardiovascular 
disease (CVD), no changes in BP or other cardiovascular 
risk biomarkers were observed after a single dose of OJ 
or a hesperidin supplement at 5 h post intake [19]. Among 
flavonoids subclasses, flavone and flavan-3-ol compounds, 
but not flavanones, were related to the prevention of hyper-
tension in a cohort of 87,242 women from the Nurses’ 
Health Study [20].
Thus, data of the antihypertensive effect of hesperidin 
consumption in humans remain controversial. Therefore, 
we assessed both the sustained and acute effects, as well as 
the influence of sustained consumption on acute effects, of 
real-life doses of OJ and a hesperidin-enriched dose on BP, 
pulse pressure (PP), and cardiovascular risk biomarkers in 
pre- and stage-1 hypertensive individuals. Our hypothesis 
was that hesperidin in OJ would provide benefits on BP 
and PP not only after sustained consumption but also at 
postprandial level after a single dose.
Materials and methods
Study population
Participants from the general population were recruited by 
means of news in the newspapers, social networks, and tab-
leaux advertisements in the Hospital Universitari Sant Joan 
(HUSJ)-Eurecat, Reus, Spain, between January 2016 and 
June 2017. From 311 subjects assessed for eligibility, 159 
(53 women and 106 men) pre- or stage-1 hypertensive indi-
viduals, according to current guidelines [21], were recruited. 
Inclusion criteria were as follows: age from 18 to 65, systolic 
blood pressure (SBP) ≥ 120 mmHg, no family history of car-
diovascular disease or chronic disease, and willingness to 
provide informed consent before the initial screening visit. 
Exclusion criteria were: body mass index (BMI) ≥ 35 kg/
m2, fasting glucose > 125 mg/dL, SBP ≥ 160 mmHg and 
diastolic blood pressure (DBP) > 100  mmHg or taking 
antihypertensive medications, hyperlipemia or antilipemic 
medication; smoking, pregnancy or intending to become 
pregnant, use of medications, antioxidants, vitamin sup-
plements or adherence to a vegetarian diet, chronic alco-
holism, physical activity > 5 h/week, intestinal disorders, 
anemia (hemoglobin ≤ 13  mg/dL in men and ≤ 12  mg/
dL in women), consumption of a research product in the 
30 days prior to inclusion in the study, or failure to follow 
the study guidelines. Participants signed informed consent 
prior to their participation in the study, which was approved 
by the Clinical Research Ethical Committee of HUSJ 
(14-12-18/12aclaassN1), Reus, Spain. The protocol and trial 
were conducted in accordance with the Helsinki Declaration 
and Good Clinical Practice Guidelines of the International 
Conference of Harmonization (GCP ICH) and were reported 
as CONSORT criteria. The trial was registered at Clinical-
Trials.gov: NCT02479568.
Intervention products
Intervention beverages (supplied by the Florida Department 
of Citrus, USA) were control drink (CD), an OJ containing 
690 mg/L of hesperidin (the natural hesperidin content), 
and an enriched orange juice (EOJ) containing 1200 mg/L 
of hesperidin. Ferrer HealthTech (Murcia, Spain) provided 
the Micronized 2S Hesperidin used in EOJ enrichment. The 
2S form, the one present naturally in the OJ, is the most 
bioavailable [18]. Beverages were analyzed for hesperidin 
and narirutin content using chromatography–mass spectrom-
etry (LC–MS/MS) (Supporting Information Table S1). Daily 
doses of 500 mL of CD, OJ and EOJ, provided 0 mg/day, 
345 mg/day, and 600 mg/day of hesperidin, and 0 mg/day, 
64 mg/day, and 77.5 mg/day of narirutin, respectively. Inter-
vention drinks were similar in appearance and smell, and 
were differentiated only by a code assigned by an independ-
ent researcher not related to the study to guarantee blind-
ing. Flavanone contents of the OJ and the EOJ were stable 
throughout the study.
Study design
A randomized, parallel, double-blind, placebo-controlled 
clinical trial was performed (Supporting Information Fig. 
S1). Participants were randomly assigned to one of the 
three intervention groups—CD, OJ, or EOJ—to consume 
500 mL/day of the corresponding beverage for 12 weeks. 
Nested within the sustained consumption study were two 
dose–response studies, one at baseline and the other after 
12 weeks of sustained consumption, where the 500 mL/
dose was administered all at once and changes in the out-
comes were recorded in the postprandial state. Participants 
were randomly allocated to the three intervention groups 
by a computerized random-number generator made by an 
independent statistician. PROC PLAN (SAS 9.2, Cary, NC: 
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83 SAS Institute Inc.) with a 1:1:1 allocation using random 
block sizes of 2, 4, and 6 was used. Participants, researchers 
and the statistician remained blinded to the type of product 
administered throughout the study.
After enrolment and following a 1-week run-in period 
with a control diet consisting of a maintained lifestyle and 
normal dietary habits based on nutritionist recommenda-
tions, the participants started the intervention trial. How-
ever, during the intervention period, the participants were 
instructed to also maintain their dietary habits, to completely 
refrain from consuming citrus-containing foods and to limit 
their total intake of flavonoid-rich foods (tea, coffee, cocoa, 
wine and other fruit juices) to reduce the possible masking 
effects that can exert these foods on BP [22, 23]. During 
the sustained study, participants attended seven visits (V) at 
the HUSJ-Eurecat. Dose–response postprandial studies, per-
formed at V1 and V7, lasted from 08:00 a.m. to 02:00 p.m., 
and participants received a light meal before leaving. In 
addition to the baseline (0 h), blood samples were collected 
at 2 h, 4 h, and 6 h after the single dose of 500 mL. The 
adherence of the volunteers to their dietary habits through-
out the study was assessed by a 3-day food record at V1, V3, 
V5, and V7. At each visit, subjects underwent a physical 
examination by a general practitioner and completed a Physi-
cal Activity Questionnaire Class AF [24], and anthropomet-
ric measurements were recorded. Samples were stored at 
-80ºC in the central laboratory’s Biobanc of HUSJ-Eurecat 
(biobanc.reus@iispv.cat) until required for batch analyses.
Compliance measures
The plasma levels of the following biomarkers of nutrient 
exposures were measured by LC–MS/MS in the plasma 
samples: hesperetin-7-O-β-d-glucuronide, hesperetin-3-O-
β-d-glucuronide, hesperetin-7-O-sulfate, naringin-4-O-β-d-
glucuronide, naringin-glucuronide and naringin sulfate. The 
extraction was carried out with a semi-automated process 
using Agilent Bravo Automated Liquid Handling Platform. 
Briefly, 20 μL of internal standard (Hesperetin d4) was 
mixed with 125 μL of plasma and 750 μL of methanol. The 
mixture was vortexed and centrifuged at 4700 rpm at 4 °C, 
and then 900 μL was evaporated in a Speed-Vac at room 
temperature. Residues were reconstituted in 25 μL of MeOH 
and 75 μL of  H2O (1% of HFor) and injected in the LC–MS/
MS, an Agilent 1200 series ultra-high-performance liquid 
chromatography (UHPLC) system coupled to a 6490 Triple 
Quad mass spectrometer, with electrospray source ionization 
(ESI) operating in negative mode.
Main outcome measures
SBP and DBP were measured twice after 2–5  min of 
respite, with the patient in a seated position, with 1-min 
interval between, using an automatic sphygmomanometer 
(OMRON HEM-907; Peroxfarma, Barcelona, Spain). The 
mean values were used for statistical analyses. Office PP, 
which represents the force that the heart generates each time 
it contracts, was determined by the difference between SBP 
and DBP [25]. The main outcomes were measured in both 
dose–response and sustained consumption studies.
Secondary outcomes
Homocysteine in serum samples was determined by LC–MS/
MS. F2α isoprostanes were determined by a quantitative 
sandwich enzyme-linked immunosorbent assay (ELISA) 
(Caymanchem, MI, USA) in 24-h urine. Soluble Intercel-
lular Adhesion Molecule-1 (ICAM-1) and Soluble Vascu-
lar Cell Adhesion Molecule-1 (VCAM-1) were determined 
in serum by the Luminex™xMAP technology with the 
EPX010-40,232-901 kit eBioscience (Thermo Fisher Scien-
tific, Waltham, Massachusetts, USA), in the the Bio-Plex™ 
200 instrument (Bio-Rad, Hercules, California, USA). Uric 
acid was measured by standardized methods on an autoana-
lyzer 182 (Beckman Coulter-Synchron, Galway, Ireland) in 
serum samples. All biological biomarkers were measured 
in the sustained consumption study. Homocysteine was 
additionally measured after the single 500-mL dose of the 
corresponding intervention product in both dose–response 
studies.
Transcriptomic analyses
Gene expression was assessed in peripheral blood mono-
nuclear cells (PBMCs) with an Agilent Microarray Plat-
form (Agilent Technologies, Santa Clara, California, USA) 
in a subsample (n = 37) of participants (11, 15, and 11, 
in CD, OJ, and EOJ groups, respectively) at baseline and 
after 12 weeks. PBMC RNA was isolated using Ficoll 
gradient separation GE Healthcare Bio Sciences, Barce-
lona, Spain), RNA yield was quantified with a Nanodrop 
UV–VIS Spectrophotometer and integrity was measured 
with an Agilent 2100 Bioanalyzer using the Total RNA 
Nano kit and the Eukaryote Total RNA Nano (Agilent 
Technologies, Santa Clara, California, USA). Total RNA 
from the PBMCs was labeled with one color (Cy3) (ref: 
5190-2305, Agilent Technologies, Santa Clara, California, 
USA) and hybridized using a Gene Expression Hybridi-
zation Kit (ref: 5188-5242, Agilent Technologies, Santa 
Clara, California, USA). Image scanning was performed 
with an Agilent Microarray Scanner System with SureScan 
 European Journal of Nutrition
1 3
High Resolution Technology (Agilent Technologies, Santa 
Clara, California, USA). Differentially expressed genes 
were subjected to functional and biochemical pathway 
analysis using Gene Ontology, Kyoto Encyclopedia of 
Genes and Genomes (KEGG) (https ://www.genom e.jp/
kegg) and PANTHER (protein annotation through evolu-
tionary relationship classification system (https ://www.
panth erdb.org/) [26] biochemical pathway databases. The 
analysis was performed using GeneCodis (https ://www.
genec odis.dacya .ucm.es [27] software.
Selected genes related to hypertension were validated 
by PCR. Briefly, to analyze the expression of the genes 
and validate the DNA array results, cDNA was synthesized 
using the High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, 4 Barcelona, Spain) and MyGene 
Series Peltier Thermal Cycler (LongGene Scientific, 
Zhejiang, China) and used for reverse transcription. The 
cDNA was subjected to quantitative reverse transcription-
polymerase chain reaction amplification using LightCycler 
480 SYBR Green I Master (Roche Diagnostic, Sant Cugat 
del Vallès, Barcelona, Spain) and a LightCycler 480 II 
system (Roche Diagnostic, Sant Cugat del Vallès, Barce-
lona, Spain).
Sample size and power analyses
A sample size of 159 individuals was calculated assuming an 
expected dropout rate of 20% and a type I error of 0.005 (two 
sided), which allows at least 80% power for the detection of 
statistically significant differences in the SBP of 4 mmHg 
among the groups. The population standard deviation of the 
SBP was estimated to equal 6 mmHg [28].
Statistical analyses
Descriptive data were expressed as the mean 95% confidence 
interval (CI). The normality of variables was assessed by 
the Kolmogorov–Smirnov test. Non-parametric variables 
were log transformed. ANOVA was used to determine dif-
ferences in baseline characteristics. Analyses were made by 
intention-to-treat. Multiple imputation was made by linear 
regression analysis. Intra-treatment comparisons were per-
formed by means of a general linear model with Bonferroni 
correction and age and sex as covariables. Inter-treatment 
comparisons were carried out by analysis of covariance 
(ANCOVA) model adjusted for age and sex. For transcrip-
tomic analyses, quality control was performed through 
principal component analyses. Statistical comparisons were 
performed by Student’s t test or Welch’s t test if proceeded. 
Multiple testing correction was performed using the Benja-
mini–Hochberg False Discovery Rate (FDR) control proce-
dure. Probes were assumed to be differentially expressed if 
they presented a P value < 0.05 and a fold change ≤ −0.58 
or ≥ 0.58 in log2 scale (corresponding to 1.5-fold difference 
in natural scale). Calculations were performed using the R 
statistical language. Comparisons among treatments were 
carried out by an ANCOVA model adjusted by age and sex 
and baseline values. Statistical significance was defined as a 
P value ≤ 0.05 for a two-sided test. Analyses were performed 
using SPSS for Windows, version 21 (IBM corp., Armonk, 




Of the 311 subjects who were assessed for eligibility, 152 
did not meet the inclusion criteria and were excluded. The 
remaining 159 participants were randomly allocated to 
the CD, OJ, and EOJ groups, (n = 53 in each group). Ulti-
mately, 129 participants completed the study (43 in the CD, 
46 in the OJ, and 40 in the EOJ groups) (Fig. 1). For the 
dose–response study, of the 52 allocated participants, three 
discontinued the intervention from the beginning, and six 
were lost for the second dose–response study. Thus, 52 par-
ticipants (17 in the CD, 21 in the OJ, and 14 in the EOJ 
groups) were available for the first dose–response study, and 
43 (13 in the CD, 18 in the OJ, and 12 in the EOJ groups) 
were available for the second dose–response study (Fig. 1). 
No differences in baseline characteristics were observed 
among the groups (Supporting Information Table S2). The 
baseline characteristics of participants in the dose–response 
study were similar to those of the whole sample. No changes 
in the level of physical activity were observed from the 
beginning to the end of the study in any group (data not 
shown). No differences in dietary intake were observed 
among groups with exception of protein (% energy) intake, 
which was greater in the OJ group than in the EOJ one 
(P = 0.031) (Supporting Information Table S3).
Compliance biomarkers
The volunteer compliance intervention was considered 
optimal because all the compliance biomarkers (hesperetin-
7-O-β-d-glucuronide, hesperetin-3-O-β-d-glucuronide, 
hesperetin-7-O-sulfate, naringerine-4-O-β-d-glucuronide, 
naringenin-glucuronide and naringenin-sulfate) increased 
significantly during the OJ and EOJ intervention compared 
with the baseline values and the CD group intervention. At 
12 weeks, the metabolite hesperetin-7-β-d-glucuronide was 
the main differentially expressed metabolite between the OJ 
and EOJ groups and the CD group (P < 0.001).
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After 12 weeks of treatments (Fig. 2a), plasma hesperetin-
7-β-d-glucuronide increased in a dose-dependent manner 
with the hesperidin content of the beverage administered 
(P < 0.001 for linear trend), and the increase in the EOJ 
group was significantly higher than that of the OJ group 
(P < 0.05). In the dose–response studies, plasma hesperetin-
7-β-d-glucuronide increased at 4 and 6 h after OJ and EOJ 
(P < 0.005 versus changes in CD), both at the beginning 
(Fig. 2b) and at the end of the study. The individual changes 
in plasma hesperetin-7-β-d-glucuronide are depicted in Sup-
plementary Fig. 4 .
Main outcomes
Changes in SBP at 2, 6, 10 and 12 weeks are shown in Fig. 3. 
SBP decreased in a dose-dependent manner with the hes-
peridin content of the beverage administered (P < 0.05 for 
linear trend). SBP decreased at weeks 4, 8, and 12 after OJ 
consumption, the decreases reaching significance versus 
changes.
in the CD at week 4 and 12 (P < 0.05) by mean 95% 
IC −5.58 (−9.8; −1.3) mmHg and −5.06 (−8.8; −1.3) 
mmHg, respectively. A borderline significance at week 8 
was also observed (P = 0.056). After consumption of EOJ, 
SBP decreased in all evaluated weeks compared to CD, 
the decreases reaching significance (P < 0.05) at all weeks, 
with the only exception of week 8 in which a borderline 
significance (P = 0.078) was observed. The average of all 
decreases through the study was −6.35 and −7.36 mmHg 
for OJ and EOJ interventions, respectively. DBP decreased 
similarly after all interventions and in all weeks (P < 0.05) 
(data not shown). Changes in PP through the study are 
shown in Fig. 4. PP decreased in a dose-dependent manner 
with the hesperidin content of the beverage administered 
(P < 0.05 for linear trend) in all weeks, but in the 12 week, 
the trend did not reach significance (P = 0.125). Concern-
ing dose–response studies, at the beginning of the study 
(Fig. 5a), significant decreases were observed in SBP at 
2 h and in PP at all evaluated times (P < 0.05) after a sin-
gle dose of 500 mL only in the case of EOJ. No changes 
were observed in DBP values. After 12 weeks of treatment 
(Fig. 5b), a single dose of 500 mL resulted in changes in 
BP and PP also only in the EOJ group (Panel B). DBP 
decreased versus baseline at all evaluated times (P < 0.05), 
and the decrease at 2 h and 6 h reached significance ver-
sus changes in CD (P < 0.05). Additionally, the observed 
Fig. 1  Flow chart of the study
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decreases in SBP at 6 h and those of PP at all evaluated 
times reached significance versus changes in CD (P < 0.05). 
At 4 h and 6 h postprandial after our, an inverse relationship 
was observed between hesperidin-7-β-d-glucuronide values 
and those of PP (R = −0.354, P = 0.023, and R = −0.377, 
P = 0.015, respectively). At 6 h, an inverse relationship was 
also observed between the increase in hesperidin-7-β-d-
glucuronide and SBP values (R = −0.353, P = 0.024).
Secondary outcomes
At week 12 after sustained consumption, homocysteine 
values decreased after OJ and EOJ treatments, and the 
decreases reached significance versus changes after the CD 
treatment. At this time point, homocysteine plasma values 
decreased in the postprandial state at 2 h and 4 h after OJ and 
after 2 h of EOJ ingestion (P < 0.05) (Fig. S2 in the online-
only Data Supplement). Uric acid decreased at 12 weeks 
after EOJ treatment, reaching significance versus changes 
in the CD treatment (P = 0.044). ICAM-1 decreased at week 
12 after EOJ treatment (P = 0.032), but no changes were 
observed between treatments. At week 12 after sustained 
consumption, uric acid concentrations were directly related 
to SBP, DBP, and PP (P < 0.05). No changes were observed 
in other secondary outcomes. After 12 weeks sustained con-
sumption, the values of SBP directly correlated with those 
of ICAM-1 (R = 0.251, P = 0.004) and VCAM (R = 0.185, 
P = 0.036) (Fig. S3 in the online-only Data Supplement), 
and the decrease in F2-isoprostanes, although without sig-
nificance, were directly correlated with the decreases in SBP 
(R = 0.178, P = 0.042).
No adverse events were reported. All products were well 
tolerated.
In transcriptomic analyses, after the sustained consump-
tion study, four genes related to hypertension were identi-
fied: Pentraxin-3 (PTX3); NLR family, pyrin domain con-
taining 3 (NLRP3); neuropeptide S receptor 1(NPSR1); and 
nicotinamide phosphoribosyl transferase (NAMPT), which 
were differentially expressed after 12 weeks of treatment. 
The expressions of the PTX3 and NAMPT genes decreased 
significantly in PBMC after the EOJ intervention versus 
the control treatment (P < 0.05). Figure 6 shows the com-
parisons among interventions considering the dot axis at 
Fig. 2  Changes in plasma hesperitin-7-β-d-glucuronide after inges-
tion of control, orange juice (OJ), and enriched OJ. a After sustained 
consumption for 12  weeks (500  mL/day). b At the beginning of 
the study after a single dose of 500  mL. *P < 0.05 versus baseline; 
†P < 0.05 versus control group; ‡P < 0.001 versus control; ¥P < 0.05 
versus OJ
Fig. 3  Changes in systolic blood pressure (SBP) at 2 (a), 6 (b), 10 (c), 
and 12 (d) weeks after sustained consumption of control drink (CD), 
orange juice (OJ), and hesperidin-enriched OJ (EOJ). *P < 0.05 ver-
sus baseline; †P < 0.05 versus CD
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P < 0.05 to be of significance. The decreases in SBP and 
PP at week 12 were directly related to the decrease in PTX3 
expression (R = 0.393, P = 0.016 and R = 0.487, P = 0.002, 
respectively). The decrease in PP at week 12 was directly 
related to that of NAMPT expression (R = 0.344, P = 0.037). 
Although no significance was observed, changes in NRLP3 
expression were inversely related to those of PP at week 
12 (R = −0.420, P = 0.010). In turn, expression of PTX3 at 
week 12 was directly related to that of NAMPT (R = 0.759, 
P < 0.001).
Discussion
In the present study, on the one hand, SBP and PP decreased 
in a dose-dependent manner with the hesperidin content of 
the beverage administered throughout the 12 weeks of the 
study. On the other hand, a single dose of 500-mL EOJ, but 
no other treatment, reduced SBP, and PP, greater changes 
when the dose was administered at the end of the study after 
12 weeks of sustained treatment where DBP changes were 
also observed. Thus, these suggested that sustained con-
sumption of hesperidin optimizes acute BP-lowering effects.
After 12  weeks, sustained EOJ consumption-related 
decreases in uric acid and ICAM were observed. Homocyst-
eine decreased at 12 weeks after OJ and EOJ, and postpran-
dial decreases in homocysteine were also present after single 
doses of OJ and EOJ at the end of the study. In agreement 
with the decrease in SBP and PP, PTX3 and NAMPT gene 
expression decreased in PBMCs at 12 weeks after sustained 
EOJ treatment.
Currently, the worldwide prevalence of hypertension 
exceeds 1.3 billion [29] and is the main risk factor for death 
and disability-adjusted life-years lost during 2010 [30]. A 
10-mmHg SBP decrease is associated with reductions of 22 
and 41% in coronary heart disease and stroke, respectively 
[31]. Decreases in SBP with medical therapies range from 5 
to 15 mmHg [32]. The average reductions in SBP through-
out our study were −6.35 and −7.36 mmHg for the OJ and 
EOJ interventions, respectively. Our data are in agreement 
with those obtained after 8–12 weeks of a treadmill exercise 
program in hypertensive individuals (6.2 mmHg) [33] and 
after consumption of the Dietary Approaches to Stop Hyper-
tension (DASH) diet (6.74 mmHg) [34] as well as with the 
results of a meta-analysis reporting a mean reduction of 
8 mmHg SBP by regular endurance exercise in hyperten-
sive patients [35]. PP, a surrogate marker of aortic stiffness, 
is recognized as a powerful and independent risk factor for 
CVD with prognostic utility beyond BP measurements [36, 
37]. Throughout our study, the average PP reductions was 
−2.41 mmHg after EOJ. A 10-mmHg increase in PP is asso-
ciated with a 13% increase in all-cause mortality and >20% 
increase in recurrent myocardial infarction [36].
Throughout the 12 weeks of sustained intervention with 
345 mg/day of hesperidin in OJ and 600 mg/day of hesperi-
din EOJ, we observed decreases in SBP and PP, but not in 
DBP. Our results are opposite of those reported in over-
weight men, with a DBP-lowering effect but not an SBP 
one, after 4 weeks of OJ or a hesperidin-rich capsule pro-
viding 292 mg and 146 mg of hesperidin/day, respectively 
[23]. No benefits on BP were reported after sustained high 
hesperidin consumption of 549 mg/L/day over 8 weeks in 
healthy elderly individuals [17]; 6 weeks at 420 mg/day in 
healthy volunteers [18]; or 3 weeks at 500 mg/day in indi-
viduals with metabolic syndrome [38]. In type 2 diabetes 
patients, however, consumption (500 mg/day) of hesperi-
din over 6 weeks led to decreases in SBP and DBP [16]. 
Differences in populations and lengths of treatment could 
account for discrepancies among studies. If the objective of 
a study is to improve a specific cardiovascular risk factor, 
subjects that present symptoms associated with the specific 
cardiovascular risk factor should be included in the study 
[39]. Thus, the present study constitutes the first RCT that 
assesses the effects of hesperidin on BP and PP in pre- and 
Fig. 4  Changes in pulse pressure (PP) at 2 (a), 6 (b), 10 (c), and 12 
(d) weeks after sustained consumption of control drink (CD), orange 
juice (OJ), and hesperidin-enriched OJ (EOJ). *P < 0.05 versus base-
line; †P < 0.05 versus CD; ‡P < 0.05 versus OJ
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stage-1 hypertensive subjects; whereas, the populations stud-
ied in other RCTs were overweight, obese or diabetic with 
no hypertension or elevated BP levels [40]. At present, few 
reports exist concerning the effect of hesperidin on PP. Hes-
peridin reversed aortic stiffness in mice [41]. Although the 
beneficial effect of flavonoids on arterial stiffness is emerg-
ing [42], our data are the first available to supporting the 
effect of dietary flavanones on human arterial stiffness.
Mechanisms by which hesperidin could contribute to 
the control of BP and PP are associated with improvements 
on endothelial function, oxidative stress, and inflammation 
[8]. Homocysteine is associated with these risk factors and 
with a renin–angiotensin system activation to induce a BP 
increase [43]. In agreement with this, we observe a decrease 
in homocysteine concomitant with decreases in BP and PP 
after hesperidin treatments. After 12-week EOJ consump-
tion, ICAM-1 values decreased, and this decrease and those 
of other inflammatory and oxidative markers were directly 
related to the SBP decrease. In our work, plasma uric acid 
decreased after 12-week EOJ consumption. Hyperuricemia 
is strongly associated with hypertension and arterial stiff-
ness through activation of the NLPR3 inflammasome [44]. 
Accordingly, in our study changes in NLPR3 gene expres-
sion after 12 weeks were inversely associated with those 
of PP. After 12 weeks of EOJ consumption, we observed 
a decrease in PBMC expression of two key hypertension-
related genes: PTX3 and NAMPT. Serum levels of PTX3, a 
marker of inflammation activation, are elevated in hyperten-
sive patients [45], and experimental studies reported a direct 
role of PTX3 in vascular function and BP homeostasis [46]. 
NAMPT, also called visfatin, is secreted by visceral fat and 
is a stimulator of proinflammatory cytokines [47]. NAMPT 
is elevated not only in hypertensive patients but also in pre-
hypertensive patients [48, 49], leading to the proposal that 
NAMPT is a marker for damage in the pre-hypertensive state 
[48]. Thus, in our study, the decrease in biochemical and 
transcriptomic markers could account for the decreases in 
BP and PP after intake of hesperidin-rich beverages.
One factor that could minimize differences among sus-
tained hesperidin interventions could be the similar contri-
bution of the narirutin present in these treatments. In experi-
mental and human studies, naringin and narirutin showed 
a hypotensive effect [12, 50, 51]. When comparing the 
dose–response results on the main outcomes, however, only 
Fig. 5  Changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP) after a single dose of 500 mL of con-
trol drink, orange juice (OJ), and enriched OJ at the beginning (a) and at the end of the study (b)a
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the EOJ single-dose intervention was capable of decreasing 
SBP, DBP, and PP at the postprandial level. At present, few 
reports exist concerning the dose–response effect of hes-
peridin consumption in humans. No changes in SBP or DBP 
have been reported at 5 h after OJ or hesperidin supplemen-
tation (containing 320 mg of hesperidin) in healthy elderly 
individuals, despite an increase in hesperidin at this time 
point [19]. The fact that a unique measurement was obtained 
after a single dose could explain differences between studies. 
To the best of our knowledge, our data are the first to report 
the postprandial benefits of a hesperidin-enriched beverage 
to BP and PP, as well as the fact that its sustained consump-
tion enhances these benefits.
The study has strengths and limitations. As a strength, 
the participants’ diets were monitored throughout the entire 
study, and avoiding hesperidin intake and limiting the con-
sumption of flavonoid-rich foods were given as dietary 
recommendations to all the participants, which is of spe-
cial interest in nutritional RCTs because these guidelines 
would limit confounding between other dietary compounds 
and the dietary intervention [40]. The dietary recommen-
dations were established equally for all the intervention 
groups (CD, OJ and EOJ), and thus, the possible changes in 
the metabolome profile and consequently the downstream 
effects on BP due to these dietary modifications would be 
equally observed in all the groups, which would result in the 
control of these changes. Another important strength is that 
this study constitutes the first human RCT that assessed a 
compliance marker, hesperitin-7-β-d-glucuronide metabo-
lite, which is associated with PP and SBP values, and thus, 
these results add robustness to our study.
Multiple measurements throughout the study permitted 
the assessment of the homogeneity of the results. One limita-
tion is the inability to assess potential interactions between 
the interventions and other dietary components. Addition-
ally, a larger sample size could have permitted detection of 
significant differences between both hesperidin treatments. 
Although BP measurements were performed with maximal 
care, a 24-h ambulatory BP monitoring could have been 
more accurate. The fact that participants were pre- and 
stage-1 hypertensive individuals limits the extrapolation of 
the results to the general population. Whether additional or 
different effects would have been observed over longer time 
periods is unknown, but longer intervention periods could 
have affected the compliance of the individuals.
In summary, our results show that the intake of hesperidin 
in OJ decreases SBP and PP after sustained consumption in 
a dose-dependent manner with the hesperidin content of the 
beverage administered. Chronic consumption of hesperidin-
rich OJ enhances the postprandial response of decreasing 
SBP, DBP and PP. Decreases in homocysteine, uric acid 
and inflammatory markers at the systemic level and in PTX3 
and NAMPT at the transcriptomic level could account for the 
observed changes in BP and PP.
Perspectives
In a randomized, controlled clinical trial with pre- and 
stage-1 hypertensive individuals, we showed that sustained 
consumption of hesperidin promoted a dose-dependent 
decrease in SBP and PP with the hesperidin content of the 
beverage administered. Our data are the first to support an 
effect of dietary flavanones on human arterial stiffness. 
Additionally, we report for the first time the postprandial 
benefits of a hesperidin-enriched beverage to BP and PP, 
as well as the fact that its sustained consumption enhances 
these benefits. Regular consumption of OJ, particularly 
hesperidin-rich OJ, could be a useful co-adjuvant tool for 
BP management in pre- and stage-1 hypertensive individu-
als. This fact has public health implications in preventive 
medicine for reducing the secondary effects of long-term 
medical treatment of mild hypertension.
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